Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis
Han Hong Lee, Hoon Hur, Soo Hong Kim, Ae Ryung Park, Wook Kim, Hae Myung Jeon
Cancer Res Treat. 2010;42(1):18-23.   Published online 2010 Mar 31     DOI: https://doi.org/10.4143/crt.2010.42.1.18
Citations to this article as recorded by Crossref logo
Prognostic significance of interim 18 F-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer
Suk-young Lee, Hyo Jung Seo, Sungeun Kim, Jae Seon Eo, Sang Cheul Oh
Asia-Pacific Journal of Clinical Oncology.2018; 14(5): e302.     CrossRef
Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
Yan-qin Lan, Ling-jun Kong, Xiao-yan Lin, Qian Xu, Xin-yan Gao, Ri-ping Wu, Xin-li Wang, Dong-ta Zhong
Cancer Chemotherapy and Pharmacology.2018; 81(6): 1007.     CrossRef
Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer
Yan-qin Lan, Ri-ping Wu, Xiao-bing Huang, Xin-li Wang, Dong-ta Zhong, Chuan-yong Huang, Jin-tian Song
Tumori Journal.2018; 104(1): 22.     CrossRef
Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status
Ilhan Hacibekiroglu, Hilmi Kodaz, Bulent Erdogan, Esma Turkmen, Asim Esenkaya, Sernaz Uzunoglu, Irfan Cicin
Asian Pacific Journal of Cancer Prevention.2015; 16(6): 2355.     CrossRef
Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer
ILHAN HACIBEKIROGLU, HILMI KODAZ, BULENT ERDOGAN, ESMA TURKMEN, ASIM ESENKAYA, YILMAZ ONAL, SERNAZ UZUNOGLU, IRFAN CICIN
Molecular and Clinical Oncology.2015; 3(5): 1160.     CrossRef
Management of advanced gastric cancer
Timothy J Price, Jeremy D Shapiro, Eva Segelov, Christos S Karapetis, Nick Pavlakis, Eric Van Cutsem, Manish A Shah, Yoon-Koo Kang, Niall C Tebbutt
Expert Review of Gastroenterology & Hepatology.2012; 6(2): 199.     CrossRef
Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang
Cancer Research and Treatment.2012; 44(4): 235.     CrossRef
Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study
K. Tsuji, H. Yasui, Y. Onozawa, N. Boku, H. Doyama, A. Fukutomi, K. Yamazaki, N. Machida, A. Todaka, H. Taniguchi, T. Tsushima, T. Yokota
Japanese Journal of Clinical Oncology.2012; 42(8): 686.     CrossRef
A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin
Isao Ito, Yasuhiko Ito, Masashi Mizuno, Yasuhiro Suzuki, Kaoru Yasuda, Takenori Ozaki, Tomoki Kosugi, Yoshinari Yasuda, Waichi Sato, Naotake Tsuboi, Shoichi Maruyama, Enyu Imai, Seiichi Matsuo
Clinical and Experimental Nephrology.2012; 16(3): 490.     CrossRef
Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status
HYEONG SU KIM, JUNG HAN KIM, HEE JUN KIM, HYUN JOO JANG, JIN BAE KIM, JI WON KIM, SO YOUNG JUNG, BYUNG CHUN KIM, DAE HYUN YANG, SOAH PARK, KEONG JU KIM, SOON IL LEE, DAE YOUNG ZANG
Oncology Letters.2012; 3(2): 425.     CrossRef
Targeted Therapies for Gastric Cancer
Jaclyn Yoong, Michael Michael, Trevor Leong
Drugs.2011; 71(11): 1367.     CrossRef